Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Inspyr Therapeutics Inc (OTCQB:NSPX)

Delayed Data
As of Apr 25
 +0.03 / +6.38%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Inspyr Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of promising, new therapeutics. It focuses on the discovery and development of prodrug cancer therapeutics for the treatment of cancerous tumors, including prostate, brain and other cancers. Its technology platform combines, plant-derived cytotoxin with a prodrug delivery system that targets the release of the drug only within the tumor. The company was founded by Craig A. Dionne, John T. Issacs and Samuel R. Denmeade on November 21, 2003 and is headquartered in San Antonio, TX.

Contact Information

Inspyr Therapeutics, Inc.
2511 North Loop 1604 West
San Antonio Texas 78258
P:(210) 479-8112
Investor Relations:



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Christopher P. LowePresident, Chief Executive Officer & Director
Ronald L. ShazerChief Medical Officer & Senior Vice President
Michael ElliottVice President-Clinical Operations
Matthew BoxerVice President & Head-Translational Medicine
David MaloneyVice President & Head-Translational Medicine